Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from 4DMedical Ltd ( (AU:4DX) ) is now available.
4DMedical Limited announced its FY2025 full-year results, highlighting a 56% increase in operating revenue and a 95% rise in SaaS revenue compared to FY2024. The company secured a $10 million strategic investment from Pro Medicus and signed a reseller agreement with Philips, enhancing its market reach. The FDA submission for its CT:VQ™ software, a non-contrast lung imaging tool, is progressing well, potentially opening a $1.1 billion market opportunity in the U.S. The company is expanding its U.S. presence with new contracts and renewals at key healthcare sites, while its global SaaS product delivery has grown significantly, now serving 388 sites.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a respiratory imaging technology company focused on commercializing and expanding its proprietary imaging technologies globally. The company specializes in non-invasive lung imaging solutions and aims to address clinical and logistical limitations in functional lung imaging.
Average Trading Volume: 1,654,075
Technical Sentiment Signal: Buy
Current Market Cap: A$253.7M
For detailed information about 4DX stock, go to TipRanks’ Stock Analysis page.